Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$397.48 USD

397.48
682,467

-0.22 (-0.06%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $397.50 +0.02 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for VRTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Vertex Pharmaceuticals Incorporated [VRTX]

Reports for Purchase

Showing records 301 - 320 ( 323 total )

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 301

09/10/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences.

Provider: WEDBUSH SECURITIES INC.

Analyst: JAMES S

Price: 10.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 302

09/08/2010

Company Report

Pages: 8

REALIZE Data Solid, Likely Beats RESPOND-2

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 303

08/24/2010

Industry Report

Pages: 22

2010 AASLD Abstract Titles Review - Second Wave Including Late-Breakers

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 75.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 304

08/20/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 305

08/04/2010

Company Report

Pages: 7

Boceprevir Topline May Be a Temporary Relief to Vertex

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 306

08/02/2010

Industry Report

Pages: 25

Biotechnology / Biopharmaceuticals -2010 AASLD Abstract Titles Review - First Wave Without Late Breakers

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 75.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 307

07/29/2010

Company Report

Pages: 9

Lowering PT to $40 on Anticipated Stronger Competition

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 308

07/16/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 309

07/12/2010

Company Report

Pages: 7

Interim TMC435 Data Impressive; Remains a Strong Competitor to Telaprevir Although >2 Years Behind

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 310

07/02/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 311

06/17/2010

Company Report

Pages: 16

Why the Lackluster Response to ADVANCE?

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 50.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 312

06/11/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 313

05/26/2010

Company Report

Pages: 17

ADVANCE Is As Good As It Can Get - Upgrade to Relative -NEUTRAL on Minimized Downside Risk.

Provider: WEDBUSH SECURITIES INC.

Analyst: XU K

Price: 50.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 314

05/17/2010

Industry Report

Pages: 17

Mid Year 2010 HCV Update.

Provider: WEDBUSH SECURITIES INC.

Analyst: XU K

Price: 50.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 315

04/28/2010

Company Report

Pages: 15

Bulls and Bears Balancing Out at EASL - What to Expect Next?

Provider: WEDBUSH SECURITIES INC.

Analyst: XU K

Price: 50.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 316

04/22/2010

Company Report

Pages: 7

Q1:10 Earnings Non-Event; Phase III Data Next

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 317

03/16/2010

Industry Report

Pages: 20

EASL 2010 Preview Part I.Summary of Oral Presentations.

Provider: WEDBUSH SECURITIES INC.

Analyst: XU K

Price: 50.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 318

03/01/2010

Company Report

Pages: 7

Telaprevir+VX-222 Combination Study Initiated

Provider: WEDBUSH SECURITIES INC.

Analyst: XU K

Price: 25.00

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 319

02/26/2010

Company Report

Pages: 2

Provider: Zacks Investment Research

Analyst: NAPODANO J

Price: 24.95

Research Provided by a Third Party

Company: Vertex Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 320

02/08/2010

Industry Report

Pages: 38

Biotech Balance Sheet

Provider: MERRIMAN CURHAN FORD & CO.

Price: 75.00

Research Provided by a Third Party